TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brii Biosciences Limited ( (HK:2137) ) has issued an update.
Brii Biosciences Limited has announced the grant of 10,120,500 share options and 2,114,000 restricted share units (RSUs) as part of its 2023 Share Option and Share Award Schemes. This move is designed to align employee interests with the company’s goals, potentially enhancing motivation and productivity. The share options granted represent approximately 1.40% of the company’s total issued shares, indicating a strategic effort to incentivize key personnel and drive company growth.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biotechnology company focused on developing innovative therapies for infectious diseases and other illnesses. The company aims to align the interests and benefits of its employees with its overall mission to maximize motivation and productivity.
Average Trading Volume: 7,439,595
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.3B
For a thorough assessment of 2137 stock, go to TipRanks’ Stock Analysis page.